|
1
|
Sanai N and Berger MS: Glioma extent of
resection and its impact on patient outcome. Neurosurgery.
62:753–766. 2018. View Article : Google Scholar
|
|
2
|
Park DM and Rich JN: Biology of glioma
cancer stem cells. Mol Cells. 28:7–12. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Raymond E, Brandes AA, Dittrich C,
Fumoleau P, Coudert B, Clement PM, Frenay M, Rampling R, Stupp R,
Kros JM, et al: European Organisation for Research and Treatment of
Cancer Brain Tumor Group Study: Phase II study of imatinib in
patients with recurrent gliomas of various histologies: A European
Organisation for Research and Treatment of Cancer Brain Tumor Group
Study. J Clin Oncol. 26:4659–4665. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Huse JT and Holland EC: Targeting brain
cancer: Advances in the molecular pathology of malignant glioma and
medulloblastoma. Nat Rev Cancer. 10:319–331. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Johnson BE, Mazor T, Hong C, Barnes M,
Aihara K, McLean CY, Fouse SD, Yamamoto S, Ueda H, Tatsuno K, et
al: Mutational analysis reveals the origin and therapy-driven
evolution of recurrent glioma. Science. 343:189–193. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Han Y, Wu Z, Wu T, Huang Y, Cheng Z, Li X,
Sun T, Xie X, Zhou Y and Du Z: Tumor-suppressive function of long
noncoding RNA MALAT1 in glioma cells by downregulation of MMP2 and
inactivation of ERK/MAPK signaling. Cell Death Dis. 7:e21232016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rahme GJ and Israel MA: Id4 suppresses
MMP2-mediated invasion of glioblastoma-derived cells by direct
inactivation of Twist1 function. Oncogene. 34:53–62. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu LY, Man XX, Yao HX and Tan YY: Effects
of pheophorbide a- mediated photodynamic therapy on proliferation
and metastasis of human prostate cancer cells. Eur Rev Med
Pharmacol Sci. 21:5571–5579. 2017.PubMed/NCBI
|
|
9
|
Tabouret E, Boudouresque F, Farina P,
Barrié M, Bequet C, Sanson M and Chinot O: MMP2 and MMP9 as
candidate biomarkers to monitor bevacizumab therapy in high-grade
glioma. Neuro Oncol. 17:1174–1176. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hu LS, Kelm Z, Korfiatis P, Dueck AC,
Elrod C, Ellingson BM, Kaufmann TJ, Eschbacher JM, Karis JP, Smith
K, et al: Impact of software modeling on the accuracy of perfusion
MRI in glioma. AJNR Am J Neuroradiol. 36:2242–2249. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Langlois B, Saupe F, Rupp T, Arnold C, van
der Heyden M, Orend G and Hussenet T: AngioMatrix, a signature of
the tumor angiogenic switch-specific matrisome, correlates with
poor prognosis for glioma and colorectal cancer patients.
Oncotarget. 5:10529–10545. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Piromkraipak P, Sangpairoj K, Tirakotai W,
Chaithirayanon K, Unchern S, Supavilai P, Power C and Vivithanaporn
P: Cysteinyl leukotriene receptor antagonists inhibit migration,
invasion, and expression of MMP-2/9 in human glioblastoma. Cell Mol
Neurobiol. 38:559–573. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Aroui S, Najlaoui F, Chtourou Y, Meunier
AC, Laajimi A, Kenani A and Fetoui H: Naringin inhibits the
invasion and migration of human glioblastoma cell via
downregulation of MMP-2 and MMP-9 expression and inactivation of
p38 signaling pathway. Tumour Biol. 37:3831–3839. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yi GZ, Feng WY, Zhou Q, Liu YW and Qi ST:
The impact of MMP-2 and its specific inhibitor TIMP-2 expression on
the WHO grade and prognosis of gliomas in Chinese population: A
Meta-Analysis. Mol Neurobiol. 54:22–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Farina P, Tabouret E, Lehmann P, Barrie M,
Petrirena G, Campello C, Boucard C, Graillon T, Girard N and Chinot
O: Relationship between magnetic resonance imaging characteristics
and plasmatic levels of MMP2 and MMP9 in patients with recurrent
high-grade gliomas treated by Bevacizumab and Irinotecan. J
Neurooncol. 132:433–437. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cho HJ, Park JH, Nam JH, Chang YC, Park B
and Hoe HS: Ascochlorin suppresses MMP-2-mediated migration and
invasion by targeting FAK and JAK-STAT signaling cascades. J Cell
Biochem. 119:300–313. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Roomi MW, Kalinovsky T, Rath M and
Niedzwiecki A: Modulation of MMP-2 and MMP-9 secretion by
cytokines, inducers and inhibitors in human glioblastoma T-98G
cells. Oncol Rep. 37:1907–1913. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ramachandran RK, Sørensen MD,
Aaberg-Jessen C, Hermansen SK and Kristensen BW: Expression and
prognostic impact of matrix metalloproteinase-2 (MMP-2) in
astrocytomas. PLoS One. 12:e01722342017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Schepkin VD: Sodium MRI of glioma in
animal models at ultrahigh magnetic fields. NMR Biomed. 29:175–186.
2016. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Krivosheya D and Prabhu SS: Combining
functional studies with intraoperative MRI in glioma surgery.
Neurosurg Clin N Am. 28:487–497. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jain KK, Sahoo P, Tyagi R, Mehta A, Patir
R, Vaishya S, Prakash N, Vasudev N and Gupta RK: Prospective glioma
grading using single-dose dynamic contrast-enhanced perfusion MRI.
Clin Radiol. 70:1128–1135. 2015. View Article : Google Scholar : PubMed/NCBI
|
